Publication: Science Translational Medicine

Ashwin V. Venkataraman, Ayla Mansurgaia, Rizzo Courtney, Bishop, Yvonne Lewis, Ece Kocagoncu, Anne Lingford-Hughes, Mickael Huibanjan Passchier, James B. Rowe, Hideo Tsukada, David J. Brooks, Laurent Martarello, Robert A. Comley, Laigao Chen, Adam J.Schwarz, Richard Hargreaves, Roger N. Gunn, Eugenii A. Rabiner and Paul M. Matthews

18 August 2022

---

Summary 

Researchers explored whether widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s Disease

View publication

Publication: Nature Neuroscience

Andrea I. Luppi, Pedro A. M. Mediano, Fernando E. Rosas, Negin Holland, Tim D. Fryer, John T. O’Brien, James B. Rowe, David K. Menon, Daniel Bor & Emmanuel A. Stamatakis

26 May 2022

---

Researchers investigated functional interactions between brain regions into synergistic and redundant components, revealing their information-processing roles.

View publication

Publication: Journal of Nuclear Medicine

Maura Malpetti, Sanne S Kaalund, Kamen A Tsvetanov, Timothy Rittman, Mayen Briggs, Kieren Allinson, Luca Passamonti, Negin Holland, P Simon Jones, Tim D Fryer, Young T Hong, Antonina Kouli, Richard Bevan-Jones, Elijah Mak, George Savulich, Maria Grazia Spillantini, Franklin Aigbirhio, Caroline H Williams-Gray, John T O’Brien and James B Rowe

18 November 2021

---

Summary

Progressive brain diseases like dementia and Parkinson’s disease move through stages. A new system to stage the dementia-parkinsonian disease known as Progressive Supranuclear Palsy (PSP) has been developed in 2020.  In 2021, researchers validated the new scheme at the Cambridge Brain Bank, looking at the disease severity at the end of life. Researchers wanted to know how the disease progresses and to stop it.

Researchers used a PET scan with a chemical “dye” called 18F-flortaucipi to measure PSP. Despite high hopes for PET using this dye to measure the burden of PSP, when the study began, the results of the study are clear – it does not support the staging of disease, either in lifetime or in terms of outcomes of the illness. 18F-Flortaucipir PET is successfully used in other diseases, like Alzheimer’s, but it cannot be used for PSP staging.

View publication

Publication: Neurobiology of Aging

David JWhiteside, P. Simon Jones, Boyd C P Ghosh, Ian Coyle-Gilchrist, Alexander Gerhard, Michele T. Hu, Johannes C Klein, P. Nigel Leigh, Alastair Church, David J Burn, Huw R Morris, James B Rowe, TimothyRittman

16 July 2021

---

Summary

This study investigated patterns of brain activity at rest in the neurodegenerative disease progressive supranuclear palsy (PSP).

The study found that participants with PSP spend more time than individuals without the disease in certain brain states, meaning their brain activity was less flexible and less efficient than normal. The time spent in these brain states was more apparent in participants who were more severely affected.

The changes in the brain’s activity did not only involve regions of the brain that are most affected by PSP, meaning that effect of the tau protein pathology of PSP has consequences across the whole brain, even where it may appear normal on a scan or have no tau pathology.

View publication

Publication: Geriatric Psychiatry

Kathy Y. Liu, Robert Howard, Sube Banerjee, Adelina Comas-Herrera, Joanne Goddard, Martin Knapp, Gill Livingston, Jill Manthorpe, John T. O’Brien, Ross W. Paterson, Louise Robinson, Martin Rossor, James B. Rowe, David J. Sharp, Andrew Sommerlad, Aida Suárez-González, Alistair Burns

16 May 2021

---

In response to a commissioned research update on dementia during the COVID-19 pandemic, a UK-based working group, comprising dementia researchers from a range of fields and disciplines, aimed to describe the impact of the pandemic on dementia wellbeing and identify priorities for future research.

View publication